Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis (REFINE)

NCT03222609 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03222609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03222609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis (REFINE)
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2017
Completion date
January 29, 2025
Enrollment
191 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis (mf)